Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Europe. The aim of this observational study is to observe the efficacy of Levemir® treatment in patients with type 2 diabetes in everyday clinical practice in Switzerland. Furthermore the time period between diagnosis of type 2 diabetes and insulin initiation is evaluated.
Interventions
DRUGinsulin detemir
Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with type 2 diabetes mellitus * Insulin-naive or currently treated with another basal insulin * Inclusion of patients at the discretion of the treating physician after the decision to prescribe Levemir®
Exclusion criteria
* Type 1 diabetes mellitus * Patients treated with short acting or with premix insulin * Women who are pregnant, breast feeding or have the intention to become pregnant * Known or suspected allergy to the study product or related product * Any
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c of treatment | after 12 to 16 weeks |
| Change in FPG (fasting plasma glucose) of treatment | after 12 to 16 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of adverse events | after 12 to 16 weeks |
| Insulin dose and concomitant oral antidiabetic medication time period between diagnosis of type 2 diabetes and insulin initiation | after 12 to 16 weeks |
Countries
Switzerland
Outcome results
None listed